GlassScriptPhysician profile
Jason A Rexroth
NPI 1568529741
$16,108.19
in general payments reported to CMS, 2019-2025
49 companies · $822 in 2025
The $822 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,784 · 2020: $357 · 2021: $469 · 2022: $1,312 · 2023: $2,406 · 2024: $3,960 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,480 · Travel and Lodging: $2,459 · Gift: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,479.74 |
| Travel and Lodging | $2,458.81 |
| Gift | $249.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,288.83 | 2019-2024 | |
| Axonics, INC. | $1,795.28 | 2022-2024 | Axonics, Bulkamid |
| Coloplast Corp | $1,612.07 | 2019-2023 | Saffron |
| Caldera Medical, INC | $1,402.55 | 2023-2025 | Desara |
| Medical Device Business Services, INC. | $1,392.34 | 2024 | Harmonic |
| Abbvie INC. | $1,156.41 | 2019-2025 | |
| Ethicon US, LLC | $648.63 | 2019-2024 | Stratafix, Harmonic, Ethicon |
| Astellas Pharma US INC | $536.81 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $464.92 | 2022-2025 | |
| Medtronic, INC. | $296.52 | 2021-2025 | Interstim, Nuro |
| Merz North America, INC. | $200.00 | 2019 | |
| Sumitomo Pharma America, INC. | $156.28 | 2023-2025 | Gemtesa, Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $147.87 | 2022 | |
| Exeltis, USA INC. | $128.67 | 2020-2024 | Slynd |
| Medtronic USA, INC. | $124.86 | 2019 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rexroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.